PPT-SHIV Infection and Drug Transporters Influence Brain Tissue Concentrations of Efavirenz

Nithya Srinivas 1 John Fallon 1 Craig Sykes 1 Nicole White 1 Amanda Schauer 1 Lou Adamson 2 Michelle Matthews 1 Paul Luciw 2 Phil Smith 1 Angela DM Kashuba 1 1 University of North Carolina at Chapel Hill Chapel Hill United States . By. T.SARITHA. M.Pharm. II sem. Pharmaceutics . UCPSc. CONTENTS. INTRODUCTION. P-glycoprotein . Distribution & Structure . Substrates&inhibitors. Mechanism of drug transport . Pharmacokinetic implications of p-gp. A . medication. . is a drug that is used to treat an illness or disease . according . to established medical guidelines. . A . drug. . is a chemical compound or substance that can alter the structure and function of the body. Psychoactive drugs affect the function of the brain, and some of these may be illegal to use and possess. . 9-1: . WHAT ARE SUBSTANCE USE DISORDERS, AND WHAT ROLES DO TOLERANCE, WITHDRAWAL, AND ADDICTION PLAY IN THESE DISORDERS?. Psychoactive drug. A chemical substance that alters perceptions and moods. Substance use . Tool . to Study Pharmacokinetics. . and . to Facilitate Drug Development. Robert B. Innis, MD, PhD. Molecular Imaging Branch. National Institute Mental Health. Outline of Talk. PET has high sensitivity and specificity. Drugs and HumanPerformance Fact Sheets - 30 - but ranges from 40-100 hours if the contribution from active metabolites is included Diazepam is metabolized to nordiazepam which is an active metabolite M.Pharm. II sem. Pharmaceutics . UCPSc. CONTENTS. INTRODUCTION. P-glycoprotein . Distribution & Structure . Substrates&inhibitors. Mechanism of drug transport . Pharmacokinetic implications of p-gp. drugs. . and. relevant . interactions. . between. antiretroviral . and. CNS . drugs. . Catia . Marzolini. Division of Infectious Diseases . & Hospital Epidemiology . www.hiv-druginteractions.org.                    !"!#$% #&'#""&"'#" ()(( . SSAT-029 STUDY . Switch to Etravirine from Efavirenz Due to CNS Toxicity . SSAT-029: Design. Source: Waters L, et al. . AIDS. 2011;25:65-71.. Immediate. . Switch Arm. Etravirine. + 2NRTI. (n = 20). Alobaidy. Reference text. Shargel. L., Yu AB. Applied Biopharmaceutics and Pharmacokinetics. Introduction. The . physicochemical characteristics of the active pharmaceutical . ingredient, . the dosage form . Pierre-Louis Toutain . Visiting Professor. . Royal Veterinary College , London . 5 July 2018. Australian & New Zealand College of Veterinary Scientists . Q. T Gold Coast, Surfers Paradise . Australia. Barb Merriman, Neurology resident, PGY-3. 27-yo female with medical history of congenital . hypoplastic. right heart admitted for worsening fatigue, SOB, and advanced hepatic fibrosis as a result of the right-sided heart failure. Already pre-approved for heart transplant, she was admitted and underwent successful cardiac transplant, and anti-rejection therapy was started . Other than acute cardiac decompensation and elevated AST and ALT, she was otherwise healthy at admission, normotensive, afebrile, no leukocytosis.. . Absorption. -Factors affecting absorption. -One compartment model. -Two compartment model. -. Bioavailabilities. and . bioequivalencies. Oral kinetics. IV infusion and multiple dosage . regemin. Metabolism. SWEET Trial . Switch to Efavirenz + TDF-FTC . SWEET: Study Design. Source: Fisher M, et al. . J Acquir Immune Defic Syndr. 2009;51:562-8.. Background. : Randomized, . controlled, open-label, phase 3 trial evaluating a simplification strategy for patients suppressed .